Key Takeaways
- R3 Technologies, led by Schloendorn and Gilman, faced scrutiny over claims of pursuing cloning for organ replacements.
- Despite denials from R3, past presentations indicated discussions around cloning techniques, including potential brainless clones.
- Experts express concerns over the ethical implications of creating human clones with significant brain deficiencies.
Controversy Surrounds R3 Technologies’ Cloning Claims
Last Monday, R3 Technologies publicly refuted findings regarding their involvement in cloning, specifically denying any intent to create “non-sentient human clones.” The company unequivocally stated that allegations of conspiracy to form cloned humans with brain damage were “categorically false.” However, co-founders Hugo Schloendorn and Alice Gilman have historically engaged in discussions about cloning, raising eyebrows within the scientific community.
In September, Schloendorn and Gilman spoke at the Abundance Longevity event, a high-profile conference focused on anti-aging initiatives. Although the presentation was intended to be confidential, an agenda revealed that Schloendorn’s session was titled “Full Body Replacement,” where the pair discussed innovative cloning techniques, including the controversial subject of personal clones intended for organ replacement. Attendees noted the use of visuals related to cloning, prompting questions about the ethicality of discussing such concepts.
Further investigation by MIT Technology Review uncovered no evidence of R3 successfully cloning any beings beyond small animals. Yet, documents showed the company’s efforts to map out a process called “body replacement cloning” alongside plans for improving cloning methods, which includes genetic blueprints for creating organisms lacking complete brain structures. This approach suggests a potential avenue for producing “organ sacks” from monkeys, aimed at creating a more ethical model for medical testing.
Despite Schloendorn’s PhD status, he is considered an outsider in biotechnology, lacking extensive publication history but gaining traction due to his unconventional methods and connections in Silicon Valley. His relationships with organizations like ARPA-H, which funds high-risk health innovations, indicate that the concept of brainless clones is garnering increased attention from broader scientific circles, even as ethical concerns remain salient.
Experts are voicing apprehension regarding the implications of such cloning practices. Jose Cibelli, a researcher with experience in human embryo cloning, expressed skepticism about safety and ethics, questioning the morality of creating beings devoid of normal brain function for the purpose of organ harvesting. He maintains that boundaries must exist in scientific exploration, underscoring the potential dangers of venturing into uncharted ethical territory.
The ongoing debates surrounding R3’s cloning projects highlight the convergence of ambition and ethical dilemmas within the biotechnology field. As this discourse evolves, it raises critical questions about the future of cloning technology and its implications for humanity.
The content above is a summary. For more details, see the source article.